|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.25 TWD | +1.79% |
|
-.--% | - |
| 27/04 | UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 12/25/12 | UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2025 | CI |
| Market Cap | 168.32Cr 5.2Cr 4.57Cr 4.25Cr 3.9Cr 7.33Cr 501.07Cr 7.44Cr 50Cr 20Cr 246.34Cr 20Cr 19Cr 851.73Cr | P/E 2024 |
-9.63x | P/E 2025 | -5.68x |
|---|---|---|---|---|---|
| Enterprise Value | 197.21Cr 6.1Cr 5.35Cr 4.98Cr 4.57Cr 8.59Cr 587.07Cr 8.72Cr 59Cr 23Cr 288.62Cr 23Cr 22Cr 997.91Cr | EV / Sales 2024 |
3.58x | EV / Sales 2025 | 3.83x |
| Free-Float |
27.79% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +1.79% |
| 3 years | 10 |  | 38.5 |
| 5 years | 10 | | 199.22 |
| 10 years | 8.34 | | 288.72 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jung Kuang Yang
CEO | Chief Executive Officer | - | - |
Meng Han Hsu
DFI | Director of Finance/CFO | - | 11/04/2016 |
Ying Yun Fan
ADM | Chief Administrative Officer | - | 01/03/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Ping-Ho Yan
BRD | Director/Board Member | - | - |
Ying Yun Fan
BRD | Director/Board Member | - | 30/06/2020 |
Feng Lin Hsu
BRD | Director/Board Member | 76 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.79% | -.--% | -.--% | -58.29% | 5.2Cr | |
| +0.86% | +1.43% | +47.17% | +163.68% | 1,06700Cr | |
| +1.59% | +4.09% | +56.51% | +52.50% | 63TCr | |
| +0.95% | +1.91% | +36.30% | +82.78% | 46TCr | |
| +1.60% | +6.25% | +37.00% | +31.03% | 35TCr | |
| -0.60% | +1.52% | +36.67% | +41.41% | 30TCr | |
| -0.14% | +0.60% | +17.29% | +18.74% | 26TCr | |
| +0.09% | -2.82% | -29.09% | -39.57% | 22TCr | |
| +1.22% | +2.66% | +22.66% | +59.87% | 20TCr | |
| -1.18% | -3.70% | +11.28% | +67.52% | 16TCr | |
| Average | +0.62% | +1.63% | +23.58% | +41.97% | 36.44TCr | |
| Weighted average by Cap. | +0.76% | +1.95% | +35.99% | +79.10% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 54Cr 1.67Cr 1.46Cr 1.36Cr 1.25Cr 2.35Cr 160.4Cr 2.38Cr 16Cr 6.31Cr 79Cr 6.25Cr 6.12Cr 272.66Cr | 51Cr 1.59Cr 1.4Cr 1.3Cr 1.19Cr 2.24Cr 153.14Cr 2.27Cr 15Cr 6.03Cr 75Cr 5.97Cr 5.84Cr 260.31Cr |
| Net income | -17Cr -53.95L -47.38L -44.06L -40.43L -75.97L -52Cr -77.14L -5.23Cr -2.04Cr -26Cr -2.03Cr -1.98Cr -88Cr | -30Cr -91.59L -80.44L -74.81L -68.65L -1.29Cr -88Cr -1.31Cr -8.88Cr -3.47Cr -43Cr -3.44Cr -3.36Cr -149.92Cr |
| Net Debt | 25Cr 76.15L 66.88L 62.2L 57.08L 1.07Cr 73Cr 1.09Cr 7.39Cr 2.89Cr 36Cr 2.86Cr 2.8Cr 124.66Cr | 29Cr 89.3L 78.43L 72.94L 66.93L 1.26Cr 86Cr 1.28Cr 8.66Cr 3.38Cr 42Cr 3.35Cr 3.28Cr 146.18Cr |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- 6562 Stock
Select your edition
All financial news and data tailored to specific country editions
